BRIEF-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand IncreasesFeb 24 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
HOTH THERAPEUTICS INC - 100% OF COHORT PATIENTS ACHIEVED PRIMARY EFFICACY ENDPOINT IN INTERIM CLEER-001 DATA
HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED REDUCTIONS IN PAIN AND ITCHING
HOTH THERAPEUTICS INC - ZERO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION
Source text: ID:nPn3Df7y0a
Further company coverage: HOTH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments